Eliem Therapeutics Quarterly Cash Flow Statements Chart
Quarterly
|
Annual
Eliem Therapeutics Quarterly Cash Flow Statements Table
Quarterly
|
Annual
| Unit: USD | 2024-03-31 |
|---|---|
| cash flows from operating activities: | |
| net income | -1,697,000 |
| adjustments to reconcile net income to net cash from operating activities: | |
| stock-based compensation | 465,000 |
| non-cash operating lease expense | 88,000 |
| accretion of discounts and amortization of premiums on investments | -63,000 |
| foreign currency gain from remeasurement | 28,000 |
| changes in operating assets and liabilities: | |
| prepaid expenses and other assets | 216,000 |
| long-term assets | 15,000 |
| accounts payable | 20,000 |
| accrued expenses and other liabilities | -745,000 |
| operating lease liabilities | -124,000 |
| long-term liabilities | -22,000 |
| net cash from operating activities | -1,819,000 |
| cash flows from investing activities: | |
| purchase of marketable securities | |
| proceeds from maturities of marketable securities | 13,751,000 |
| net cash from investing activities | 13,751,000 |
| cash flows from financing activities: | |
| proceeds from the exercise of stock options | 15,000 |
| net cash from financing activities | 15,000 |
| effect of exchange rate changes on cash and cash equivalents | -28,000 |
| net change in cash and cash equivalents | 11,919,000 |
| cash and cash equivalents at beginning of period | 93,112,000 |
| cash and cash equivalents at end of period | 105,031,000 |
| supplemental disclosure of cash operating activities: | |
| cash paid for leases included in operating cash outflows | 133,000 |
| supplemental disclosure of non-cash investing and financing activities: | |
| deferred transaction costs accrued but not yet paid | 952,000 |
| right-of-use assets obtained in exchange for lease liabilities | |
| right-of-use asset impairment | |
| foreign currency (gain) income from remeasurement | |
| proceeds from exercise of stock options | |
| effect of exchange rate changes on cash | |
| supplemental disclosure of cash flow information: |
We provide you with 20 years of cash flow statements for Eliem Therapeutics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Eliem Therapeutics stock. Explore the full financial landscape of Eliem Therapeutics stock with our expertly curated income statements.
The information provided in this report about Eliem Therapeutics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.